Alm, Your right. Hikma needs to weigh potential for profit against loss. A settlement would be the way to avoid setting precedent.
When you are trying to calculate damages it is important to remember it's not about generic sales. It's about lost revenue for Amarin. Gv presence in the market lead to formulary changes. Those changes hurt our profit.
Settlement timing.(if there is one) The longer Hikma keeps gv on the market the greater the risk. The damage figure would be increasing with every passing day. If Hikma does the math and settlement is the answer, I would think it would happen rather quickly.
Supply is limiting the potential for generic profit. This supply issue does not necessarily limit their exposure to damages.
At what point does selling gv become more of a problem than it's worth?
We will see.
Sleven,
News 
Market Data 
Discover 
